The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis

Abstract

Atherosclerosis is one of the leading causes of death and disability worldwide. It is a complex disease characterized by lipid accumulation within the arterial wall, inflammation, local neoangiogenesis, and apoptosis. Innate immune effectors, in particular monocytes and macrophages, play a pivotal role in atherosclerosis initiation and progression. Although most of available evidence on the role of monocytes and macrophages in atherosclerosis is derived from animal studies, a growing body of evidence elucidating the role of these mononuclear cell subtypes in human atherosclerosis is currently accumulating. A novel pathogenic role of monocytes and macrophages in terms of atherosclerosis initiation and progression, in particular concerning the role of these cell subsets in neovascularization, has been discovered. The aim of the present article is to review currently available evidence on the role of monocytes and macrophages in human atherosclerosis and in relation to plaque characteristics, such as plaque neoangiogenesis, and patients’ prognosis and their potential role as biomarkers.

The Role of Bone Morphogenetic Protein 7 (BMP-7) in Inflammation in Heart Diseases

“…Monocyte polarization plays a key role in the progression of various inflammatory diseases such as atherosclerosis, myocardial infarction, and diabetic cardiomyopathy [236][237][238]. Infiltrated monocyte differentiation depends on the tissue microenvironment they reside in and the external stimuli they receive [239].…”

Macrophage-Based Therapies for Atherosclerosis Management

“…Due to the increased circulation time and homing capabilities, the platform may be loaded with therapeutics with diverse physical properties and hence show promise for use in magnetic resonance imaging applications. Nevertheless, the former method of directly loading drugs into macrophages has some deficiencies in preparation, such as low loading efficiency, premature drug release, and undesirable drug inactivation [61,104,105]. Therefore, the macrophage membrane-camouflaged drug carrier has been developed by using the macrophage membrane to further coat the drug carrier on the surface.…”

Lipid‐based gene delivery to macrophage mitochondria for atherosclerosis therapy

“…Among the risk factors of atherosclerosis are dyslipidemia, arterial hypertension, diabetes mellitus, and old age 3 . Monocytes and macrophages play leading roles at all stages of atherosclerosis development, contributing to the local inflammatory response, cholesterol accumulation, and plaque growth 4 …”